Pluri (PLUR) Competitors $4.10 -0.15 (-3.53%) Closing price 03:47 PM EasternExtended Trading$4.10 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CTOR, CCCC, GLSI, MOLN, ANIX, ABOS, BTMD, TVGN, ZYBT, and TILShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Citius Oncology (CTOR), C4 Therapeutics (CCCC), Greenwich LifeSciences (GLSI), Molecular Partners (MOLN), Anixa Biosciences (ANIX), Acumen Pharmaceuticals (ABOS), biote (BTMD), Tevogen Bio (TVGN), Zhengye Biotechnology (ZYBT), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Citius Oncology C4 Therapeutics Greenwich LifeSciences Molecular Partners Anixa Biosciences Acumen Pharmaceuticals biote Tevogen Bio Zhengye Biotechnology Instil Bio Pluri (NASDAQ:PLUR) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Which has more volatility and risk, PLUR or CTOR? Pluri has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Which has preferable earnings & valuation, PLUR or CTOR? Citius Oncology has lower revenue, but higher earnings than Pluri. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.34M24.97-$22.58M-$5.17-0.79Citius OncologyN/AN/AN/AN/AN/A Do insiders & institutionals have more ownership in PLUR or CTOR? 16.6% of Pluri shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 6.7% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to PLUR or CTOR? In the previous week, Citius Oncology had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for Pluri. Pluri's average media sentiment score of 1.84 beat Citius Oncology's score of 0.00 indicating that Pluri is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Citius Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend PLUR or CTOR? Pluri presently has a consensus price target of $12.00, suggesting a potential upside of 192.68%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 235.20%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is PLUR or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to Pluri's net margin of -1,701.19%. Citius Oncology's return on equity of -51.93% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-1,701.19% -4,191.91% -88.27% Citius Oncology N/A -51.93%-22.17% SummaryCitius Oncology beats Pluri on 9 of the 12 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.66M$3.48B$6.17B$10.68BDividend YieldN/A2.27%5.70%4.84%P/E Ratio-0.7923.3929.4727.36Price / Sales24.97485.50589.24132.03Price / CashN/A45.2825.8230.35Price / Book-37.2710.6112.526.69Net Income-$22.58M-$52.56M$3.32B$276.59M7 Day Performance-8.48%4.94%2.43%0.97%1 Month Performance-14.49%16.10%8.78%3.95%1 Year Performance-13.68%14.51%62.11%36.40% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri2.4477 of 5 stars$4.10-3.5%$12.00+192.7%-10.6%$34.66M$1.34M-0.79150Positive NewsCTORCitius Oncology2.0751 of 5 stars$1.76+1.5%$6.00+241.7%+37.1%$146.65MN/A0.00N/AGap UpCCCCC4 Therapeutics3.5829 of 5 stars$2.03-4.0%$8.50+319.8%-62.7%$145.54M$35.58M-1.29150Gap UpGLSIGreenwich LifeSciences1.2498 of 5 stars$10.45+1.5%$42.00+301.9%-29.9%$143.81MN/A-7.763MOLNMolecular Partners1.4962 of 5 stars$3.56-6.2%$8.00+125.0%-22.1%$143.55M$5.65M-1.71180Positive NewsGap UpANIXAnixa Biosciences2.9063 of 5 stars$4.31-4.8%$9.00+109.1%+36.2%$142.51M$210K-12.375News CoverageHigh Trading VolumeABOSAcumen Pharmaceuticals2.9478 of 5 stars$2.30+8.3%$7.00+205.0%-29.0%$140.52MN/A-1.0220BTMDbiote2.1719 of 5 stars$2.83-1.0%$6.00+112.0%-46.6%$140.41M$197.19M3.16194TVGNTevogen Bio2.6954 of 5 stars$0.70-1.6%$10.00+1,320.5%-59.2%$138.68MN/A-3.713ZYBTZhengye BiotechnologyN/A$2.88+0.7%N/AN/A$135.85M$25.53M0.00278TILInstil Bio3.0444 of 5 stars$19.73-3.2%$88.50+348.6%-49.1%$133.75MN/A-1.53410Positive NewsGap Up Related Companies and Tools Related Companies Citius Oncology Competitors C4 Therapeutics Competitors Greenwich LifeSciences Competitors Molecular Partners Competitors Anixa Biosciences Competitors Acumen Pharmaceuticals Competitors biote Competitors Tevogen Bio Competitors Zhengye Biotechnology Competitors Instil Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
